153888-27-8 Usage
Uses
Used in Pharmaceutical Industry:
(3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-ethyl-piperidine is used as a potential pharmaceutical candidate for medicinal applications due to its unique structure and stereochemistry.
Used in Medicinal Chemistry Research:
(3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-ethyl-piperidine is used as a compound of interest in medicinal chemistry research to explore its potential properties and applications in drug development.
Note: The specific applications and reasons for using (3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-ethyl-piperidine are not provided in the materials. The uses listed above are based on the general potential of compounds with similar structures in the pharmaceutical and medicinal chemistry fields. Further research and testing would be needed to determine the specific properties and potential uses of (3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-ethyl-piperidine.
Check Digit Verification of cas no
The CAS Registry Mumber 153888-27-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,8,8 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 153888-27:
(8*1)+(7*5)+(6*3)+(5*8)+(4*8)+(3*8)+(2*2)+(1*7)=168
168 % 10 = 8
So 153888-27-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H20FNO/c1-2-16-8-7-14(12(9-16)10-17)11-3-5-13(15)6-4-11/h3-6,12,14,17H,2,7-10H2,1H3/t12-,14-/m0/s1
153888-27-8Relevant articles and documents
Structural determinants influencing the potency and selectivity of indazole-paroxetine hybrid G protein-coupled receptor kinase 2 inhibitors
Bouley, Renee,Waldschmidt, Helen V.,Cato, M. Claire,Cannavo, Alessandro,Song, Jianliang,Cheung, Joseph Y.,Yao, Xin-Qiu,Koch, Walter J.,Larsen, Scott D.,Tesmer, John J.G.
supporting information, p. 707 - 717 (2017/11/23)
G protein-coupled receptor kinases (GRKs) phosphorylate activated receptors to promote arrestin binding, decoupling from heterotrimeric G proteins, and internalization. GRK2 and GRK5 are overexpressed in the failing heart and thus have become therapeutic
Process for the production of paroxetine
-
, (2008/06/13)
A process for the production of paroxetine is described, wherein N-substituted derivatives of 4-(p-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine are treated according to the following sequence of reactions: (a) hydrogenation catalyzed by transition metal complexes with chiral diphosphinic ligands; (b) —OH derivatisation and nucleophilic substitution, the substituent being sesamol; (c) N-dealkylation. The process is highly stereospecific and brings about the formation of intermediates enriched with the desired isomeric components, which are converted into paroxetine in quantitative yields.
